$NEXI
NexImmune, Inc.

2024 Q3 Form 10-Q Financial Statement

#000162828024035598 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $647.4K
YoY Change -86.74%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.509M
YoY Change -54.92%
Operating Profit -$3.509M
YoY Change -54.92%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.183M
YoY Change 442.06%
Pretax Income
YoY Change
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.327M
YoY Change -69.25%
Net Earnings / Revenue
Basic Earnings Per Share -$1.69
Diluted Earnings Per Share -$1.69
COMMON SHARES
Basic Shares Outstanding 1.395M shares 1.371M shares
Diluted Shares Outstanding 1.380M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.424M
Short-Term Investments
Other Short-Term Assets $40.64K
YoY Change -86.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.127M
YoY Change -83.1%
LONG-TERM ASSETS
Property, Plant & Equipment $1.107M
YoY Change -72.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.628M
YoY Change 442.24%
Total Long-Term Assets $2.734M
YoY Change -45.02%
TOTAL ASSETS
Total Short-Term Assets $3.127M
Total Long-Term Assets $2.734M
Total Assets $5.861M
YoY Change -75.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.281M
YoY Change 119.94%
Accrued Expenses $3.455M
YoY Change -32.77%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.737M
YoY Change -24.43%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.737M
Total Long-Term Liabilities
Total Liabilities $4.941M
YoY Change -23.65%
SHAREHOLDERS EQUITY
Retained Earnings -$228.0M
YoY Change 9.93%
Common Stock $139.00
YoY Change -94.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $696.4K
YoY Change
Total Liabilities & Shareholders Equity $5.861M
YoY Change -75.03%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$2.327M
YoY Change -69.25%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity File Number
EntityFileNumber
001-40045
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1394671 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2646 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
226101118 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222594047 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1391396 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2082494 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
842446 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
23577853 usd
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Type
DocumentType
10-Q
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
507751 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
3126863 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1106608 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1627829 usd
CY2024Q2 us-gaap Assets
Assets
5861300 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1281161 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3455430 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4736591 usd
CY2024Q2 us-gaap Liabilities
Liabilities
4940761 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
NEXIMMUNE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
42-2518457
dei Entity Address Address Line1
EntityAddressAddressLine1
9119 Gaither Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Gaithersburg,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20877
dei City Area Code
CityAreaCode
301
dei Local Phone Number
LocalPhoneNumber
825-9810
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
NEXI
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7566504 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
734464 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352901 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
46716 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1793373 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3679105 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
68809 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5084232 usd
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2023Q4 us-gaap Liabilities
Liabilities
5084232 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1394671 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2424112 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3202452 usd
CY2024Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000 usd
CY2024Q2 us-gaap Assets Held For Sale Long Lived Fair Value Disclosure
AssetsHeldForSaleLongLivedFairValueDisclosure
175000 usd
CY2023Q4 us-gaap Assets Held For Sale Long Lived Fair Value Disclosure
AssetsHeldForSaleLongLivedFairValueDisclosure
1444043 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5400959 usd
CY2023Q4 us-gaap Assets
Assets
8593949 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1336318 usd
CY2024Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
204170 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
224189 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Central Index Key
EntityCentralIndexKey
0001538210
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1394671 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1066320 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1066320 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
139 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
228694296 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-227998085 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
696350 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3509717 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5861300 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8593949 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
647373 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4880338 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11004382 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2904321 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4095937 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6605686 usd
CY2024Q2 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
779439 usd
CY2023Q2 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
0 usd
us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
779439 usd
us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
0 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
3509306 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
7784659 usd
us-gaap Operating Expenses
OperatingExpenses
6266772 usd
us-gaap Operating Expenses
OperatingExpenses
17610068 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3509306 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7784659 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6266772 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-17610068 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
31870 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
223321 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
46660 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
498059 usd
CY2024Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1185373 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2606212 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
CY2024Q2 nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0 usd
CY2023Q2 nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0 usd
nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
-1111614 usd
nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0 usd
CY2024Q2 nexi Offering Costs Expense
OfferingCostsExpense
0 usd
CY2023Q2 nexi Offering Costs Expense
OfferingCostsExpense
0 usd
nexi Offering Costs Expense
OfferingCostsExpense
740836 usd
nexi Offering Costs Expense
OfferingCostsExpense
0 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-34702 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5166 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
62312 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19572 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1182541 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
218155 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
862734 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
478487 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2326765 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7566504 usd
us-gaap Net Income Loss
NetIncomeLoss
-5404038 usd
us-gaap Net Income Loss
NetIncomeLoss
-17131581 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.25
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.42
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1380395 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1380395 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1043138 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1043138 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1043138 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1043138 shares
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3509717 usd
CY2024Q1 nexi Stock And Warrants Issued During Period Value New Issues
StockAndWarrantsIssuedDuringPeriodValueNewIssues
212777 usd
CY2024Q1 nexi Warrants Issued And Exercised During Period Value
WarrantsIssuedAndExercisedDuringPeriodValue
1973240 usd
CY2024Q1 nexi Reclassifications Of Permanent To Temporary Equity
ReclassificationsOfPermanentToTemporaryEquity
224189 usd
CY2024Q1 nexi Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Contingently Redeemable Warrants
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfContingentlyRedeemableWarrants
224189 usd
CY2024Q1 nexi Adjustments To Additional Paid In Capital Reverse Stock Split Value
AdjustmentsToAdditionalPaidInCapitalReverseStockSplitValue
0 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
348301 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3077273 usd
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
224189 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2742573 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
0 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
280542 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2326765 usd
CY2024Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
224189 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
696350 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32300484 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9565077 usd
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
991133 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
17002482 usd
us-gaap Net Income Loss
NetIncomeLoss
-5404038 usd
us-gaap Net Income Loss
NetIncomeLoss
-17131581 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
190320 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
530922 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-779439 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
30105 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2606212 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 usd
nexi Derivative Liabilities Offering Costs
DerivativeLiabilitiesOfferingCosts
740836 usd
nexi Derivative Liabilities Offering Costs
DerivativeLiabilitiesOfferingCosts
0 usd
nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
-1111614 usd
nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
628843 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1833579 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
46716 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
263815 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-236264 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-472188 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-165544 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-55157 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1794864 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-223675 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2211999 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-68809 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-275641 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4488420 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18313581 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47739 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
566131 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
566131 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47739 usd
nexi Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
3143949 usd
nexi Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3143949 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-778340 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18361320 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3222452 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34697340 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2444112 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16336020 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228000000.0 usd
CY2024Q2 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2400000 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2424112 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3202452 usd
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
20000 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
20000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2444112 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3222452 usd
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
304731 shares
CY2024Q2 nexi Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
76701 usd
CY2023Q4 nexi Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
115353 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
335400 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
368048 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
55010 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
35817 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
40640 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215246 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
507751 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
734464 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2669035 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2907702 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1562427 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1554801 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1106608 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352901 usd
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
100000 usd
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
300000 usd
CY2024Q2 nexi Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
2845138 usd
CY2023Q4 nexi Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3148021 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
351062 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
389858 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
259230 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
131226 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3455430 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3679105 usd
CY2024Q2 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
0 usd
CY2023Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
50000 usd
CY2024Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2023Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2022Q4 nexi Restructuring And Related Cost Expected Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent
0.30
CY2022Q4 nexi Restructuring And Related Cost Number Of Positions Before Eliminations
RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations
74 employee
CY2022Q4 nexi Restructuring And Related Cost Number Of Positions After Eliminations
RestructuringAndRelatedCostNumberOfPositionsAfterEliminations
50 employee
CY2022Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
700000 usd
CY2023Q3 nexi Restructuring And Related Cost Number Of Positions Before Eliminations
RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations
44 employee
CY2023Q3 nexi Restructuring And Related Cost Number Of Positions After Eliminations
RestructuringAndRelatedCostNumberOfPositionsAfterEliminations
6 employee
CY2023Q3 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
3100000 usd
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
266537 usd
us-gaap Restructuring Charges
RestructuringCharges
0 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
26470 usd
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
240067 usd
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
nexi Preferred Stock Consideration Received Cash
PreferredStockConsiderationReceivedCash
0.01 usd
nexi Preferred Stock Consideration Received Cash
PreferredStockConsiderationReceivedCash
0.01 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1394671 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1394671 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1066320 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1066320 shares
CY2024Q1 nexi Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
-1100000 usd
CY2024Q1 nexi Fundamental Transaction Clause Beneficial Ownership Percentage Threshold
FundamentalTransactionClauseBeneficialOwnershipPercentageThreshold
0.50
CY2024Q1 nexi Fundamental Transaction Clause Beneficial Ownership Percentage Threshold
FundamentalTransactionClauseBeneficialOwnershipPercentageThreshold
0.50
CY2023Q1 us-gaap Share Price
SharePrice
0.41
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
280542 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
991133 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
628843 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1833579 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
130526 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.64
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
nexi Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
11287 shares
nexi Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
21.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1688 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.25
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
117551 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
117551 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
29.59
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y10M24D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
80469 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.32
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
37082 shares
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
12.83
nexi Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
CY2024Q2 nexi Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1200000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-2326765 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7566504 usd
us-gaap Net Income Loss
NetIncomeLoss
-5404038 usd
us-gaap Net Income Loss
NetIncomeLoss
-17131581 usd
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.69
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.69
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.25
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.42
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1380395 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1380395 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1043138 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1043138 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1315447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1315447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1043138 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1043138 shares
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
443613 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
219491 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
443613 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
219491 shares
CY2022Q1 nexi Related Party Transaction Term
RelatedPartyTransactionTerm
P2Y
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
200000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001628280-24-035598-index-headers.html Edgar Link pending
0001628280-24-035598-index.html Edgar Link pending
0001628280-24-035598.txt Edgar Link pending
0001628280-24-035598-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nexi-20240630.htm Edgar Link pending
nexi-20240630.xsd Edgar Link pending
nexi-20240630xexx311.htm Edgar Link pending
nexi-20240630xexx312.htm Edgar Link pending
nexi-20240630xexx321.htm Edgar Link pending
nexi-20240630xexx322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
nexi-20240630_cal.xml Edgar Link unprocessable
nexi-20240630_def.xml Edgar Link unprocessable
nexi-20240630_lab.xml Edgar Link unprocessable
nexi-20240630_pre.xml Edgar Link unprocessable
nexi-20240630_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending